[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Deciphera Pharmaceuticals, LLC\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":197},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,45,70,83,109,134,175],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100053362","phase-1-a-study-of-inlexisertib-dcc-3116-in-combination-with-anticancer-therapies-in-participants-with-advanced-malignancies-100053362",false,"NCT05957367","A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies","A Master Protocol for the Multi-Cohort, Phase 1\u002F2 Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies","Inclusion Criteria:\n\n* Male or female ≥18 years of age\n* Module A: Part 1 and Part 2:\n\nModule A Part 1 and Part 2 inlexisertib combination closed on January 8, 2024, with no participants enrolled.\n\n* Module B: Only for Part 1 (Safety\u002FDose-finding):\n\n  * Pathologically confirmed diagnosis of GIST with a KIT or platelet-derived growth factor receptor alpha (PDGFRA) mutation\n  * Must have progressed on at least one approved systemic regimen given in the locally advanced or metastatic setting or have documented intolerance to it\n  * Must not have received prior ripretinib treatment\n* Module B: Only for Part 2 (Expansion)\n\n  * Pathologically confirmed GIST with documented mutation in KIT exon 11\n  * Must have progressed on imatinib given in the locally advanced or metastatic setting or have been intolerant to imatinib and may not have received additional systemic therapy for GIST\n* Must have at least 1 measurable lesion according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST)\n* Must have a life expectancy of more than 3 months and an ECOG performance status of 0-1\n* Adequate organ function and bone marrow reserve based on laboratory assessments performed at Screening\n* Must provide a fresh tumor biopsy, if able\n\nExclusion Criteria:\n\n* Must not have received the following within the specified time periods prior to the first dose of study drug:\n\n  1. Medications, including anticancer therapies, that are known strong or moderate inhibitors or inducers of CYP3A4 or P-glycoprotein (P-gp) including certain herbal medications (eg, St. John's wort): 14 days or 5×the half-life of the medication (whichever is longer)\n  2. Other anticancer therapies and any investigational therapies with a known safety and PK profile: 14 days or 5×the half-life of the medication (whichever is shorter)\n  3. Investigational therapies with unknown safety and PK profile: 28 days. If there is enough data on the investigational therapy to assess the risk for drug-drug interactions and late toxicities of prior therapy as low, the Sponsor's Medical Monitor may approve a shorter washout of 14 days\n  4. Grapefruit or grapefruit juice: 14 days\n* Have not recovered from all clinically relevant toxicities from prior therapy\n* New York Heart Association Class III or IV heart disease, active ischemia, or any other uncontrolled cardiac condition, clinically significant cardiac arrhythmia requiring therapy, uncontrolled hypertension, congestive heart failure, or myocardial infarction within 6 months prior to the first dose of study drug\n* Symptomatic central nervous system (CNS) metastases or presence of leptomeningeal disease\n* Malabsorption syndrome\n* Radiation for indications other than bone disease must have been completed 4 weeks prior to first dose of study drug, unless it consisted of limited field palliative radiation, including whole brain radiation, which must have been completed at least 2 weeks prior to first dose of study drug\n* Major surgery within 4 weeks of the first dose of study drug\n* Active HIV, Hepatitis B or Hepatitis C infection","ALL","18 Years",{"count":19,"type":20},94,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This is a Phase 1\u002F2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of inlexisertib in combination with anticancer therapies. Modules within the master protocol are defined according to different combinations of inlexisertib with other anticancer agents.",[27],"GIST",[29,30,31],"Advanced gastrointestinal stromal tumors","gastrointestinal stromal tumors","ripretinib","RECRUITING","2026-07-10",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":36},"2023-09-28",{"date":40,"type":20},"2029-03",{"name":42,"class":43},"Deciphera Pharmaceuticals, LLC","INDUSTRY",27,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":53,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100634392","phase-1-evaluate-the-effect-of-vimseltinib-on-pharmacokinetics-of-combined-oral-contraceptive-ethinyl-estradiollevonorgestrel-100634392","NCT07539090","Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol\u002FLevonorgestrel)","A Phase 1, Open-label, Fixed-sequence Study to Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol\u002FLevonorgestrel) in Healthy Female Participants","Inclusion Criteria:\n\n1. Participants are in good general health, as required by the protocol and as determined by Principal Investigator.\n2. Body mass index (BMI) from greater than or equal to (≥) 18.5 to less than or equal to ≤ 30 kilogram per square meter (kg\u002Fm\\^2).\n3. Adequate organ function, blood and urine tests, as required by the protocol and as determined by Principal Investigator.\n\nExclusion Criteria:\n\n1. History or presence of clinically significant diseases of the neurological, dermatological, renal, hepatic, gastrointestinal, cardiovascular, or musculoskeletal systems or history or presence of clinically significant psychiatric, immunological, endocrine, or metabolic disease as determined by Principal Investigator.\n2. Unwilling or unable to comply with the requirements of the protocol.\n3. Determined by Principal Investigator to be unsuitable to participate in the study for any other reason.",true,"FEMALE","55 Years",{"count":56,"type":20},24,[23],"The main purpose of this study is to determine the effect of vimseltinib on pharmacokinetics of combined oral contraceptive (COC) (ethinyl estradiol\u002Flevonorgestrel) in healthy female participants. This study will last approximately 35 days.",[60],"Healthy Participants","2026-06-15",{"date":63,"type":36},"2026-06-17",{"date":65,"type":36},"2026-06-05",{"date":67,"type":20},"2026-08",{"name":42,"class":43},1,{"id":71,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":21,"phases":73,"briefSummary":25,"conditions":74,"keywords":75,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":80,"leadSponsor":81,"locationsCount":82},"100512816",{"count":19,"type":20},[23,24],[27],[29,30,31],"2026-06-01",{"date":78,"type":36},"2026-06-02",{"date":38,"type":36},{"date":40,"type":20},{"name":42,"class":43},26,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":21,"phases":92,"briefSummary":93,"conditions":94,"keywords":98,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},"100590331","phase-1-study-of-dcc-2812-in-participants-with-advanced-genitourinary-cancers-100590331","NCT06966024","Study of DCC-2812 in Participants With Advanced Genitourinary Cancers","An Open-label, Phase 1 Study of DCC-2812 Monotherapy in Participants With Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer","Key Inclusion Criteria:\n\n* Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer\n* Able to take oral medication\n* If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements\n* Adequate organ function and electrolytes\n\nKey Exclusion Criteria:\n\n* Received any prior anticancer therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-2812\n* Impaired cardiac function\n* Major surgery within 28 days of the first dose of study drug",{"count":91,"type":20},60,[23],"This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced\u002Fmetastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.",[95,96,97],"Renal Cell Carcinoma","Urothelial Carcinoma","Castration-resistant Prostate Cancer",[99],"Advanced malignancies","2026-05-18",{"date":102,"type":36},"2026-05-20",{"date":104,"type":36},"2025-08-27",{"date":106,"type":20},"2029-02",{"name":42,"class":43},5,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":21,"phases":118,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":133},"100564519","phase-1-a-master-protocol-to-evaluate-dcc-3009-in-gastrointestinal-stromal-tumor-gist-100564519","NCT06630234","A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)","A Master Protocol for the Multi-cohort, Open-label, Phase 1\u002F2 Study of DCC-3009 in Participants With Gastrointestinal Stromal Tumor (GIST)","Inclusion Criteria:\n\nModule A Part 1 (Escalation):\n\n* Any participant with histologically or cytologically confirmed advanced\u002Funresectable or metastatic GIST with documented KIT or platelet-derived growth factor receptor alpha (PDGFRA) mutation, who has progressed on or was intolerant to at least 1 approved tyrosine kinase inhibitor (TKI) regimen in the advanced\u002Fmetastatic setting\n* Have at least 1 measurable lesion as defined by mRECIST, v1.1\n* Have Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1\n* Adequate organ function, bone marrow function, and electrolytes\n* All participants agree to comply with the contraception requirements\n* Have a life expectancy of more than 3 months\n\nExclusion Criteria:\n\n* Received systemic anticancer therapy or radiotherapy within 14 days prior to first dose of study drug\n* Prior or concurrent malignancy that requires treatment or is expected to require treatment for active cancer\n* Has known active central nervous system (CNS) metastases or an active primary CNS cancer\n* History or presence of clinically relevant cardiovascular abnormalities\n* Major surgery within 28 days of the first dose of study drug\n* Had systemic arterial thrombotic or embolic events within 6 months prior to the first dose of study drug\n* Had venous thrombotic events (e.g., deep vein thrombosis) or venous thrombotic embolic events (e.g., pulmonary embolism) within 1 month prior to the first dose of study drug\n* Known allergy or hypersensitivity to any component of the study drug\n* Malabsorption syndrome or other illness that could affect oral absorption\n* Any other clinically significant comorbidities",{"count":117,"type":20},120,[23,24],"The purpose of this Phase 1\u002F2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module being defined according to therapy: DCC-3009 alone or DCC-3009 in combination with other anticancer therapies. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). Participants will be treated in 28-day treatment cycles with an estimated duration of up to 2 years.",[121],"Gastrointestinal Stromal Tumor (GIST)",[123,124],"PDGFRA mutations","KIT mutations","2026-02-03",{"date":127,"type":36},"2026-02-05",{"date":129,"type":36},"2024-12-10",{"date":131,"type":20},"2028-05",{"name":42,"class":43},10,{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":21,"phases":143,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":82},"100563699","phase-2-a-study-to-evaluate-vimseltinib-in-adults-with-active-chronic-graft-versus-host-disease-cgvhd-100563699","NCT06619561","A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)","A Phase 2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy","Inclusion Criteria:\n\n1. Must be allogeneic hematopoietic stem cell transplant (HSCT) recipients with moderate to severe cGVHD requiring systemic immune suppression.\n\n   a. May have persistent active acute GVHD (aGVHD) and chronic GVHD (cGVHD) manifestations (overlap syndrome).\n2. Participants with active cGVHD who have received and failed at least 2 prior lines of systemic therapy.\n3. Stable dose of systemic corticosteroids is permitted but not required. If being taken, participants should be on a stable dose of corticosteroids for at least 2 weeks prior to starting study drug treatment.\n4. Adequate organ and bone marrow functions.\n5. Participants of reproductive potential agree to follow the contraception requirements.\n6. Karnofsky Performance Scale (KPS) of ≥60.\n\nExclusion Criteria:\n\n1. Has aGVHD without manifestations of cGVHD.\n2. Prior use of colony-stimulating factor 1 receptor (CSF1R) inhibitor for cGVHD.\n3. History or other evidence of severe illness, uncontrolled infection, or any other conditions that would make the participant unsuitable for the study. All wounds must be healed and free of infection or dehiscence.\n4. History of malignancy except for:\n\n   1. Underlying malignancy for which the transplant was performed\n   2. Malignancy treated with curative intent and with no evidence of active disease present for more than 3 years prior to enrollment and felt to be at low risk for recurrence.\n5. Malabsorption syndrome or other illness that could affect oral absorption.",{"count":142,"type":20},48,[24],"The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years.",[146],"Chronic Graft-Versus-Host Disease (cGVHD)",[148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166],"Allogeneic hematopoietic stem cell transplant (HSCT)","Graft-Versus-Host Disease","GVHD","cGVHD","Graft versus host disease","Immune System Diseases","Organizing Pneumonia","Bronchiolitis Obliterans","Bronchiolitis","Bronchial Diseases","Respiratory Tract Diseases","Lung Diseases, Obstructive","Lung Diseases","Bronchiolitis Obliterans Syndrome","Graft vs Host Disease","Sclerosis","Fibrosis","Hematopoietic stem cell transplantation","Liver diseases","2025-12-12",{"date":169,"type":36},"2025-12-15",{"date":171,"type":36},"2024-11-21",{"date":173,"type":20},"2029-10",{"name":42,"class":43},{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":182,"targetDuration":184,"studyType":185,"phases":4,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":69},"100598744","tenosynovial-giant-cell-tumor-tgct-real-world-participant-experience-with-vimseltinib-100598744","NCT07075471","Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib","Real-World Patient Experience of Vimseltinib for the Treatment of Tenosynovial Giant Cell Tumor","Inclusion Criteria:\n\n1. Diagnosis of TGCT according to medical records\n2. Prescribed vimseltinib per the approved label requirements. Participants are eligible if either (A) the decision to receive vimseltinib has been made but treatment has not yet been initiated or (B) the decision to receive vimseltinib has been made and participant has received first dose of prescribed vimseltinib less than 6 months prior to study enrollment\n3. Has provided informed consent and medical records release\n\nExclusion Criteria:\n\n1. Participant has received any other systemic agent for the treatment of TGCT during the 6 months prior to starting treatment with vimseltinib\n2. Participant has received the first dose of prescribed vimseltinib in the current treatment course more than 6 months before study enrollment\n3. Participant is active in an interventional clinical trial of vimseltinib",{"count":183,"type":20},100,"12 Months","OBSERVATIONAL","The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT.\n\nThis study will collect data in an observational disease registry involving no intervention to the participants and will not influence standard medical care or impact treatment decisions for participants.",[188],"Tenosynovial Giant Cell Tumor","2025-11-04",{"date":191,"type":36},"2025-11-05",{"date":193,"type":36},"2025-09-03",{"date":195,"type":20},"2027-09",{"name":42,"class":43},""]